Search research articles
Contact Us
Filters
Showing results (71-80 of 131) with videos related to
Page
of 14
Sort By:
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))
|
November 3, 2022
[Further Development and Interoperability in Oncological Care Structures, Quality Control and Research]
Monika Klinkhammer-Schalke, Simone Wesselmann, Johannes Bruns, et al.
Journal of Medicinal Chemistry
|
September 5, 2023
Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders
Susanne Roehrig, Jens Ackerstaff, Eloísa Jiménez Núñez, et al.
BMC Health Services Research
|
February 25, 2021
Guideline-based quality assurance: a conceptual framework for the definition of key elements
Elena Parmelli, Miranda Langendam, Thomas Piggott, et al.
Journal of Medicinal Chemistry
|
December 8, 2022
BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor
Daniel Meibom, Sina Micus, Anna Lena Andreevski, et al.
Journal of Medicinal Chemistry
|
November 2, 2013
5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor
Jerome Meneyrol, Markus Follmann, Gilbert Lassalle, et al.
Breast (Edinburgh, Scotland)
|
November 7, 2025
Evaluation of breast cancer screening programmes: Candidate performance indicators and their association with breast cancer mortality
Carlos Canelo-Aybar, Pablo Alonso-Coello, Sergei Muratov, et al.
Journal of Medicinal Chemistry
|
June 11, 2025
Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy
Hartmut Beck, Stefanie Mesch, Stefanie Zimmermann, et al.
BMC Health Services Research
|
February 25, 2021
Bringing two worlds closer together: a critical analysis of an integrated approach to guideline development and quality assurance schemes
Thomas Piggott, Miranda Langendam, Elena Parmelli, et al.
BMC Cancer
|
August 25, 2020
Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators
Sergei Muratov, Carlos Canelo-Aybar, Jean-Eric Tarride, et al.
Annals of Internal Medicine
|
February 28, 2022
Integrating Quality Assurance and Quality Improvement With Guidelines: Systematic Stakeholder-Driven Development of an Extension of the Guidelines International Network-McMaster Guideline Development Checklist
Thomas Piggott, Miranda W Langendam, Elena Parmelli, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 131) with videos related to
Sort By:
Page
of 14
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))
|
November 3, 2022
[Further Development and Interoperability in Oncological Care Structures, Quality Control and Research]
Monika Klinkhammer-Schalke, Simone Wesselmann, Johannes Bruns, et al.
Journal of Medicinal Chemistry
|
September 5, 2023
Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders
Susanne Roehrig, Jens Ackerstaff, Eloísa Jiménez Núñez, et al.
BMC Health Services Research
|
February 25, 2021
Guideline-based quality assurance: a conceptual framework for the definition of key elements
Elena Parmelli, Miranda Langendam, Thomas Piggott, et al.
Journal of Medicinal Chemistry
|
December 8, 2022
BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor
Daniel Meibom, Sina Micus, Anna Lena Andreevski, et al.
Journal of Medicinal Chemistry
|
November 2, 2013
5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor
Jerome Meneyrol, Markus Follmann, Gilbert Lassalle, et al.
Breast (Edinburgh, Scotland)
|
November 7, 2025
Evaluation of breast cancer screening programmes: Candidate performance indicators and their association with breast cancer mortality
Carlos Canelo-Aybar, Pablo Alonso-Coello, Sergei Muratov, et al.
Journal of Medicinal Chemistry
|
June 11, 2025
Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy
Hartmut Beck, Stefanie Mesch, Stefanie Zimmermann, et al.
BMC Health Services Research
|
February 25, 2021
Bringing two worlds closer together: a critical analysis of an integrated approach to guideline development and quality assurance schemes
Thomas Piggott, Miranda Langendam, Elena Parmelli, et al.
BMC Cancer
|
August 25, 2020
Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators
Sergei Muratov, Carlos Canelo-Aybar, Jean-Eric Tarride, et al.
Annals of Internal Medicine
|
February 28, 2022
Integrating Quality Assurance and Quality Improvement With Guidelines: Systematic Stakeholder-Driven Development of an Extension of the Guidelines International Network-McMaster Guideline Development Checklist
Thomas Piggott, Miranda W Langendam, Elena Parmelli, et al.
Page
of 14